TICKERNERD
Menu
CABACABAHealthcare · Biotechnology

CABA Stock Forecast: Cabaletta Bio, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$1.52
+4.47% on the day

The 10 Wall Street analysts covering Cabaletta Bio, Inc. hold a median 12-month price target of $14 — +788.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$246.7M
Ticker Nerd rank
21/ 100
Median analyst target
$14
Analysts covering
10
Revenue$0.0
Operating income−$52.0M
Net income−$51.0M
Free cash flow−$41.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
−24.0%
YTD
−30.6%
1Y
−44.5%
From 52W high
−63.4%
From 52W low
+12.6%
$1.35
$4.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CABA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cabaletta Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
21/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
64
Growth
59
Accruals
54
Revisions
43
Momentum
33
Volatility
22
Value
21
Quality
21
Issuance
18

Size (64): Smaller than most of the companies we track.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CABA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CABA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00Jan 26Apr 26Jul 26Oct 26CABAHigh $30Median $14Low $3

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $3Median $14High $30

The green dot is the last close — the median target sits +788.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$16
14 Aug 2026Wells FargoMaintainsEqual-Weight—
14 Aug 2026Wells FargoMaintainsEqual-Weight$4.00 → $3.00
15 May 2026Wells FargoMaintainsEqual-Weight$2.00 → $4.00
15 May 2026Wells FargoMaintainsEqual-Weight—
4 May 2026Cantor FitzgeraldReiteratesOverweight—
24 Mar 2026GuggenheimMaintainsBuy—
24 Mar 2026Morgan StanleyMaintainsOverweight—
31 Oct 2025Cantor FitzgeraldMaintainsOverweight—
10 Oct 2025HC Wainwright & Co.ReiteratesBuy—
5 Sept 2025Cantor FitzgeraldReiteratesOverweight—
14 Aug 2025CitigroupMaintainsBuy—
8 Aug 2025GuggenheimMaintainsBuy—
8 Aug 2025Wells FargoMaintainsEqual-Weight—
11 June 2025HC Wainwright & Co.ReiteratesBuy—
16 May 2025CitigroupMaintainsBuy—
16 May 2025GuggenheimMaintainsBuy—
15 May 2025GuggenheimMaintainsBuy—
1 Apr 2025GuggenheimReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CABA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CABA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Cabaletta Bio, Inc. returned −44.5% against +13.6% for the S&P 500, dividends included.

CABA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26CABAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CABA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Cabaletta Bio, Inc. (CABA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
1.2×

Cheaper than 65% of US stocks

EV / EBITDA
−0.3×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−93.2%

Higher than 14% of US stocks

Return on assets
−48.2%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cabaletta Bio, Inc. (CABA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cabaletta Bio, Inc. has a market value of $246.7M and an enterprise value of $47.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$181.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$154.2M.

  • Shares outstanding: 167.7M.

  • Trailing P/E: −0.7×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cabaletta Bio, Inc. employs 154 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

CABA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CABACabaletta Bio, Inc.$246.7M21
LXEOLexeo Therapeutics, Inc.$245.8M27
FATEFate Therapeutics, Inc.$252.3M96
ACIUAC Immune SA$241.2M29
IFRXInflaRx NV$254.8M9
IMRXImmuneering Corp.$257.6M36
LCTXLineage Cell Therapeutics, Inc.$259.1M61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cabaletta Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CABA news & analysis

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

Seeking Alpha · 13 Oct 2026positive

Seeking Alpha described Cabaletta Bio as trading 40% below an estimated $2.41 pipeline value, while noting its single-asset risk. It highlighted rese-cel’s planned mid-2027 pivotal Phase 1/2 data and late-2027 BLA submission, as well as a 10-year Cellares manufacturing deal intended to lower future costs.

Why it matters — CABA watchers may weigh rese-cel’s development timeline and potential manufacturing cost benefits against the company’s single-asset risk and cash concerns.

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 5 Oct 2026neutral

Cabaletta Bio announced it granted inducement equity awards to four newly hired non-executive employees as a material inducement to their employment, with the awards approved under Nasdaq Listing Rule 5635(c)(4).

Why it matters — This signals the company is adding new staff through standard stock-based hiring incentives, which could be of interest to CABA shareholders monitoring management and talent changes.

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Cabaletta Bio, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The item consists of the transcript of the company's presentation at the event.

Why it matters — A transcript of Cabaletta's presentation at a major healthcare conference provides CABA watchers with direct insight into the company's management commentary and positioning.

Cabaletta Bio to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Cabaletta Bio announced plans to participate in the Wells Fargo 21st Annual Healthcare Conference, holding investor meetings on September 8, 2026, in Boston, MA.

Why it matters — CABA watchers would care because the company's scheduled investor meetings provide an opportunity for engagement with the financial community at a major healthcare conference.

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Cabaletta Bio reported second quarter 2026 financial results and provided a business update. The company stated that registrational RESET-Myositis clinical data remain on track to be reported in mid-2027, supporting a planned BLA submission for rese-cel in the second half of 2027.

Why it matters — This update confirms that rese-cel, the company's key pipeline candidate, is on schedule for registrational data and a near-term regulatory filing, signaling steady progress toward a potential commercial launch.

FAQ

Frequently asked questions about CABA stock

What is the CABA stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Cabaletta Bio, Inc. have a median 12-month price target of $14, with estimates ranging from $3 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CABA stock a buy right now?

Of the 10 analysts covering Cabaletta Bio, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cabaletta Bio, Inc. 21 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CABA?

As at 28 Oct 2026, Cabaletta Bio, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (64 of 100).

Will CABA stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +788.2% from the last close, and Ticker Nerd's factor model ranks Cabaletta Bio, Inc. 21 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CABA stock forecast for 2030?

No analyst covering Cabaletta Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CABA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $30 over the next 12 months.

How has CABA stock performed over the past year?

Cabaletta Bio, Inc. returned -44.5% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cabaletta Bio, Inc. do?

Cabaletta Bio Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases.

What is the latest news on CABA?

The most recent item we track (Seeking Alpha, 13 Oct 2026): "Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns". Seeking Alpha described Cabaletta Bio as trading 40% below an estimated $2.41 pipeline value, while noting its single-asset risk. It highlighted rese-cel’s planned mid-2027 pivotal Phase 1/2 data and late-2027 BLA submission, as well as a 10-year Cellares manufacturing deal intended to lower future costs.

Company

About Cabaletta Bio, Inc.

Cabaletta Bio Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company’s current programs center on targeted cell therapies designed to selectively eliminate disease-causing B cells while sparing healthy immune function. Its lead candidate, rese-cel, is being studied in the RESET clinical development program across autoimmune conditions including lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta Bio also advances CAAR T cell approaches through its broader CABA platform, which is intended to address B cell–mediated autoimmune disorders. Based in Philadelphia, Cabaletta Bio plays a specialized role in the cell therapy market by focusing on precision immunology and disease-modifying treatments for patients with severe autoimmune disease.

CEO Dr. Steven A. Nichtberger M.D. · 154 employees · United States · https://www.cabalettabio.com